ReviewOncology letters2026
Cervical cancer immune microenvironment: Mechanisms of HPV-mediated immune evasion and advances in immunotherapy (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comparative effectiveness of immune checkpoint inhibitors in squamousTranslational cancer research · 2026Article
- Metastasis of Breast Lobular Carcinoma to the Uterine Cervix: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Therapeutic Vaccines for Chronic Viral Infections: From Immune Modulation to Clinical Translation.Vaccines · 2026Review
- The Microbiome-Mitochondria-Extracellular Vesicle Axis in HPV Persistence and Cervical Carcinogenesis.Genes · 2026Review
- Efficacy of immune checkpoint inhibitors plus chemotherapy versus chemotherapy-based control in cervical cancer: a meta-analysis.American journal of cancer research · 2026Review
- Mitochondrial reprogramming in cervical cancer: crosstalk with tumor immunity, HPV oncogenic signaling, and therapeutic resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer, strongly associated with persistent infection by high-risk human papillomaviruses 16/18 (HPV 16/18), remains a major global health burden. The tumor immune microenvironment (TIME) of cervical cancer plays a decisive role in tumor progression and therapeutic outcomes, where HPV oncoproteins E5, E6 and E7 disrupt antigen presentation, interfere with interferon signaling, activate immune checkpoints and induce metabolic reprogramming, thereby establishing an immunosuppressive TIME. Therapeutic advances, including immune checkpoint inhibitors (e.g., pembrolizumab in KEYNOTE-826, nivolumab in CheckMate 358), therapeutic vaccines and adoptive cell therapies, have shown promise but face challenges such as low response rates, resistance, stromal barriers and microbiome-related influences. The aim of the present review is to summarize the current understanding of the cervical cancer TIME, elucidate HPV-mediated immune evasion mechanisms, and to highlight recent advances and ongoing challenges in immunotherapy. Future directions include combination strategies, novel immune targets, and precision approaches integrating spatial multi-omics and microbiota modulation, which may improve immunotherapy efficacy and support personalized treatments for cervical cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.